Aqilion's CEO: "We are driven by dealmaking and scientific data"

With four standalone programs in its pipeline, Swedish biotech company Aqilion is positioned for many exciting upcoming milestones. The company's CEO Sarah Fredriksson visited BioStock's studio to talk about the status of the programs, what to take away from the pre-IND meeting with the FDA, and how the company's previous giant deal with Merck has shaped the company - both internally and in its efforts to create new partnerships.